Altimmune, Inc. ALT
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
4/9
Piotroski F — financial health
0.63
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $41,000 | -$88.1M | — | -$67.5M | $224.9M |
| 2024 | $20,000 | -$95.1M | — | — | $123.5M |
| 2023 | $426,000 | -$88.4M | — | -$75.9M | $194.1M |
| 2022 | -$68,000 | -$84.7M | — | -$62.7M | $185.3M |
| 2021 | $4.4M | -$97.1M | — | -$90.4M | $199.1M |
| 2020 | $8.2M | -$49.0M | — | -$34.5M | $225.9M |
Why these scores methodology →
Piotroski F-score: 4/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 0.63 (distress)
- Working capital / assets 0.94
- Retained earnings / assets -2.32
- EBIT / assets -0.338
- Equity / liabilities 4.086
Source: SEC EDGAR filings · CIK 0001326190 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.